Mpox (Monkeypox): Symptoms, Transmission, Treatment, and Prevention

What Is Mpox?

Mpox (formerly monkeypox) is a viral zoonosis caused by the monkeypox virus (Orthopoxvirus genus, related to smallpox). Two clades exist: Clade I (Central Africa, more severe) and Clade II (West Africa, responsible for the 2022 global outbreak).

Symptoms (Typically 5–21 Days Post-Exposure)

  • Prodrome (0–5 days): Fever, headache, myalgia, backache, lymphadenopathy (distinguishes from smallpox), chills, exhaustion.
  • Rash progression: Macules → papules → vesicles → pustules → scabs → heal. Often starts on face/oral mucosa and spreads centrifugally. The 2022 Clade IIb variant frequently presents with anogenital/perioral onset and fewer lesions.
  • Duration: 2–4 weeks. Infectious until all scabs separate and fresh skin forms.

Transmission

  • Close contact: Skin-to-skin (rash, scabs), respiratory droplets (prolonged face-to-face), mucosal contact (kissing, sex).
  • Fomites: Contaminated bedding, towels, clothing, surfaces.
  • Vertical: Pregnant person to fetus/newborn.
  • Animal: Bite/scratch, bushmeat preparation (endemic regions).

Not airborne like measles or COVID-19.

Risk Groups (2022 Outbreak)

  • GBMSM (gay, bisexual, and other men who have sex with men) – sexual networks drove spread.
  • Sex workers, people with multiple partners.
  • Immunocompromised individuals (HIV/CD4 <200 → severe disease).
  • Pregnant women, children under 8.

Diagnosis

PCR on lesion swab (roof/fluid/scab). Orthopoxvirus positive → confirmatory MPXV PCR. Available at commercial labs and LRN.

Treatment

  • Supportive: Pain control (topical lidocaine, oral analgesics), hydration, skin care (antiseptic washes), treat secondary bacterial infection.
  • Antivirals (tecovirimat/TPOXX): FDA-approved for smallpox; expanded access (EA-IND) for mpox. Prioritized for severe/immunocompromised/ocular/mucosal involvement. Oral/IV formulations.
  • VIGIV: Vaccinia immune globulin for severe immunodeficiency.

Prevention

  • Vaccination: JYNNEOS (MVA-BN) – 2-dose series, 28 days apart. Pre-exposure (PrEP) for high-risk; post-exposure (PEP) ≤4 days (ideal) to 14 days. ACAM2000 (live replicating) – alternative, more side effects.
  • Behavioral: Reduce partners, avoid skin-to-skin contact with symptomatic individuals, don't share linens/utensils.
  • Hygiene: Handwashing, surface disinfection (EPA List Q).
  • Isolation: Until all lesions healed.

Current Status

The 2022 global outbreak (Clade IIb) has been largely controlled in high-income countries through vaccination and behavior change. Endemic transmission persists in Central/West Africa. WHO maintains surveillance.

Viral Infections - Related Articles